Effect of Vitamin D supplementation in treatment of First episode Psychosis

Not Applicable

Completed

• Conditions: Health Condition 1: F23- Brief psychotic disorderHealth Condition 2: null- First Episode PSychosisHealth Condition 3: F323- Major depressive disorder, singleepisode, severe with psychotic featuresHealth Condition 4: F302- Manic episode, severe with psychotic symptomsHealth Condition 5: F200- Paranoid schizophrenia

• Registration Number: CTRI/2017/07/009136
• Lead Sponsor: Central Institute of Psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2015-06-20
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

1. Either sex.

2. Age: 18-45 years.

3. Diagnosed cases of a. Schizophrenia (all subtypes) b. Mania with psychotic symptoms c. Severe Depression with psychotic symptoms d. Acute & Transient Psychotic Disorder ; fulfilling ICD-10 DCR (WHO, 1993) criteria.

4. Status of patient should be drug naïve (or drug free for minimum 4 weeks for oral psychotropic medications & 8 weeks for depot preparations).

5. Patients giving written informed consent.

Exclusion Criteria

1. Presence of co-morbid psychiatric disorder. 2. Individuals with history of substance use meeting dependence criteria, other than nicotine & caffiene.

3. Co-morbid medical illness known to affect Vit.D level (Arthritis, Osteoporosis, Rickets, End Stage Renal Disease, Malabsorption Syndromes, Corticosteroid therapy).

4. Patients already on Vitamin D supplementation.

5. Patients receiving anticonvulsant medications as mood stabilizer.

6. Patients with BMI more than 30kg/m².

7. Menopausal females.

Study & Design

• Study Type: Interventional
• Study Design: Not specified